CN120091828A - 含有肽、表面活性剂和聚合物的组合物 - Google Patents

含有肽、表面活性剂和聚合物的组合物 Download PDF

Info

Publication number
CN120091828A
CN120091828A CN202380071490.1A CN202380071490A CN120091828A CN 120091828 A CN120091828 A CN 120091828A CN 202380071490 A CN202380071490 A CN 202380071490A CN 120091828 A CN120091828 A CN 120091828A
Authority
CN
China
Prior art keywords
group
meth
peptide
acrylate
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380071490.1A
Other languages
English (en)
Chinese (zh)
Inventor
坂口真菜
岩田智哉
真贝太规
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2022/038128 external-priority patent/WO2023063376A1/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN120091828A publication Critical patent/CN120091828A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08Cellulose derivatives
    • C08L1/26Cellulose ethers
    • C08L1/28Alkyl ethers
    • C08L1/284Alkyl ethers with hydroxylated hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08Cellulose derivatives
    • C08L1/32Cellulose ether-esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
CN202380071490.1A 2022-10-12 2023-10-11 含有肽、表面活性剂和聚合物的组合物 Pending CN120091828A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JPPCT/JP2022/038128 2022-10-12
PCT/JP2022/038128 WO2023063376A1 (ja) 2021-10-13 2022-10-12 ペプチド化合物及び界面活性剤を含む組成物
EP22200995.3 2022-10-12
EP22200995.3A EP4166133B1 (en) 2021-10-13 2022-10-12 Composition containing peptide compound and surfactant
JP2022-211372 2022-12-28
JP2022211372 2022-12-28
JP2023068715 2023-04-19
JP2023-068715 2023-04-19
PCT/JP2023/036892 WO2024080308A1 (ja) 2022-10-12 2023-10-11 ペプチド、界面活性剤及びポリマーを含む組成物

Publications (1)

Publication Number Publication Date
CN120091828A true CN120091828A (zh) 2025-06-03

Family

ID=90669612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380071490.1A Pending CN120091828A (zh) 2022-10-12 2023-10-11 含有肽、表面活性剂和聚合物的组合物

Country Status (5)

Country Link
EP (1) EP4582092A1 (https=)
JP (1) JPWO2024080308A1 (https=)
CN (1) CN120091828A (https=)
TW (1) TW202428307A (https=)
WO (1) WO2024080308A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026004834A1 (ja) * 2024-06-25 2026-01-02 中外製薬株式会社 固体分散体、及びそれを含む組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
KR20120039763A (ko) * 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
AU2012271691A1 (en) * 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
CN104853749A (zh) * 2012-09-17 2015-08-19 塔瑞克斯制药有限公司 血管紧张素的口服制剂
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
MX2022014886A (es) * 2020-05-29 2023-01-04 Seagen Inc Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法

Also Published As

Publication number Publication date
TW202428307A (zh) 2024-07-16
JPWO2024080308A1 (https=) 2024-04-18
EP4582092A1 (en) 2025-07-09
WO2024080308A1 (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
ES2613608T3 (es) Composiciones sólidas
CA2338256C (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
HRP20020182A2 (en) Benzamide formulation with histone deacetylase inhibitor activity
TW200303204A (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
ES2560052T3 (es) Nueva combinación
CS417791A3 (en) Capsules or tablets with a controlled release
CN120091828A (zh) 含有肽、表面活性剂和聚合物的组合物
HUP0000850A2 (hu) Balszalazidszármazékokat tartalmazó új gyógyszerforma
WO2014054880A1 (ko) 신규한 폴리에틸렌글리콜과 비타민 씨를 함유하는 안정성이 개선된 장관 하제 조성물
WO2023214509A1 (ja) 界面活性剤と併用するためのペプチド化合物を含む組成物
EP4166133B1 (en) Composition containing peptide compound and surfactant
JP7247122B2 (ja) ベリノスタットの新規経口製剤
HK40120690A (zh) 含有肽、表面活性剂和聚合物的组合物
WO2025220686A1 (ja) ペプチド、糖脂肪酸エステル構造を有する界面活性剤及び(メタ)アクリル酸系ポリマーを含む医薬組成物
JPWO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
WO2013119002A1 (ko) 폴리에틸렌글리콜과 비타민 씨를 함유하는 장관 하제 조성물
EA039150B1 (ru) Новые пероральные составы на основе белиностата
JP2004035535A (ja) 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法
KR20100057423A (ko) 덱시부프로펜의 염 및 이를 함유하는 경구용 약학 조성물의제조방법
WO2003055886A1 (en) Amorphous substance of tricyclic triazolobenzazepine derivative
RS53324B (sr) Stabilna formulacija amorfnih soli perindoprila, postupak za njihovu pripremu, naročito industrijsku pripremu, i njihova upotreba u terapiji hipertenzije
CA2952950C (en) Antimicrobial compositions with effervescent agents
TW200423972A (en) Tablet having improved solubility
CN120418354A (zh) 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法
WO2025037251A1 (en) Solid dispersions of niraparib or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40120690

Country of ref document: HK